Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company...
Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company...
Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company Common Stock
Pulse Biosciences，2024年12月18日，公司的联席主席和主要股东Robert W. Duggan行使了他在公司2024年配股中获得的所有Warrants，相当于5840万美元，共计5,306,156股公司普通股。
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Company common stock. Mr. Duggan also confirmed that, from December 11, 2024 through this past Friday, December 13, 2024, he has purchased an additional 156,714 shares of Pulse Biosciences. These transactions bring Mr. Duggan's current ownership in the Company to approximately 70%.
Pulse Biosciences, Inc.（纳斯达克：PLSE）（"公司"或"Pulse Biosciences"），是一家商业化CellFX系统的创新生物电医学公司，该系统由纳米脉冲刺激（NPS）科技驱动。今天宣布，2024年12月18日，公司联席主席和主要股东Robert W. Duggan行使了他在公司2024年配股获得的所有Warrants，相当于5840万美元，总计5,306,156股公司普通股。Duggan先生还确认，从2024年12月11日至刚过去的2024年12月13日，他又购买了156,714股Pulse Biosciences的股份。这些交易使Duggan先生在公司的当前持股比例约为70%。
